|
Congressional:
Senate HELP Committee Holds Markup on 8 Health Care Bills
On Wednesday, the Senate Health, Education, Labor, and Pensions (HELP) Committee held a markup on eight health care bills, 7 of which passed, and the remaining bill, the Ensuring Timely Access to Generics Act of 2025, was deferred to a later date after the committee voted in favor of an amendment that would cap the price of insulin at $35 per month for people with commercial insurance. Chairman Bill Cassidy (R-LA) stated that he was committed to working with Ranking Member Bernie Sanders (I-VT) or Senator Susan Collins (R-ME) to refine the amendment moving forward.
-
S. 1782, Charlotte Woodward Organ Transplant Discrimination Prevention Act (Agreed to by Roll Call Vote, 22-0)
-
S. 3799, Healthy Start Reauthorization Act of 2026 (Agreed to by Roll Call Vote, 22-0)
-
S. 4109, Stem Cell Therapeutic and Research Reauthorization Act (Agreed to by Roll Call Vote, 22-0)
-
S. 2339, EARLY Act Reauthorization of 2025 (Agreed to by Roll Call Vote, 22-0)
-
S. 4472, Accelerating Access to Critical Therapies for ALS Act of 2026 (Agreed to by Roll Call Vote, 22-0)
-
S. 2658, Medication Affordability and Patent Integrity Act (Agreed to by Roll Call Vote, 16-6)
-
S. 1954, Biosimilar Red Tape Elimination Act (Agreed to by Roll Call Vote, 22-0)
-
S. 3014, Ensuring Timely Access to Generics Act of 2025 (Vote deferred to a later date)
Read Mehlman’s markup summary here.
Senator Wyden Seeks Input on New Policies to Lower Drug Prices
On Tuesday, Senate Finance Committee Ranking Member Ron Wyden (D-OR) and Senators Catherine Cortez Masto (D-NV), Peter Welch (D-VT), Ruben Gallego (D-AZ), Mark Kelly (D-AZ), Tammy Baldwin, (D-WI), Maggie Hassan (D-NH), Jeff Merkley (D-OR), Chris Van Hollen (D-MD), Tammy Duckworth (D-IL), and Richard Blumenthal (D-CT), released a request for information (RFI) on a host of proposals aimed at lowering the cost of prescription drugs. The RFI focuses on three policy objectives:
- Lowering the price manufacturers charge for prescription drugs
- Lowering out-of-pocket costs for patients
- Fostering biopharmaceutical innovation in areas of unmet need, bolstering domestic clinical trials, and recruiting and maintaining scientific talent
Read the press release here and the RFI here.
Notable Bills:
Senators Young, Colleagues Introduce Bipartisan Bill to Make Biological Data a Strategic National Resource
On Tuesday, Senators Todd Young (R-IN), Alex Padilla (D-CA), Mike Rounds (R-SD), and Andy Kim (D-NJ) introduced the Web of Biological Data Act to create a comprehensive, national biological database accessible to American researchers and innovators. The legislation would direct the Secretary of Energy to establish the Web of Biological Data (WOBD), a single point of entry for U.S. researchers to securely access high-quality, AI-ready biological datasets from different sources. Representatives Matt Van Epps (R-TN) and Jake Auchincloss (D-MA) introduced companion legislation in the House. Read the press release here and the bill here.
Executive Branch:
CMS Issues Medicare Drug Price Negotiation Program Proposed Rule
Late last week, on Friday, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that would codify the Medicare Drug Price Negotiation Program for initial price applicability year 2029 and beyond, moving the program from implementation through program instruction and other forms of guidance into a regulatory framework. The proposal would allow CMS to select up to 20 additional negotiation-eligible Part D and/or Part B drugs for 2029 and each subsequent cycle, and would establish policies for negotiation and renegotiation of maximum fair prices, including manufacturer agreements, data submissions, offer and counteroffer processes, deselection, and publication of agreed-upon MFPs. CMS also proposes targeted program-integrity changes, including a narrow modification to the treatment of certain fixed-combination drugs and new formulations, and would implement the Temporary Floor for Small Biotech Drugs for 2029 and 2030. For Part D, the rule would codify requirements that selected drugs with a maximum fair price (MFP) in effect be included on formularies and that negotiated prices paid by plans not exceed the MFP plus dispensing fees. CMS frames the proposal as intended to lower prescription drug costs for Medicare beneficiaries, provide greater predictability for stakeholders, support continued innovation, and strengthen the long-term administration of the Negotiation Program. Comments on the proposed rule are due August 17, 2026. Read the press release here, the fact sheet here, and the proposed rule here.
CMS Releases Strengthening CMS Oversight of Accrediting Organizations Final Rule
Late last week, on Friday, the Centers for Medicare & Medicaid Services (CMS) released the final rule, Strengthening Oversight of AO and Preventing AO Conflicts of Interest. The final rule is intended to ensure that organizations responsible for overseeing more than 9,000 healthcare providers and suppliers use Medicare standards and create greater consistency between State Survey Agencies (SAs) and Accrediting Organizations (AOs) in their respective survey processes. Additionally, the rule creates a new process for monitoring AO performance; establishes consistent standards, processes, and definitions; updates validation and performance systems; requires AO surveyors to take the same CMS training as SA surveyors; and streamlines the CMS AO validation process. Read the press release here, and the fact sheet here.
CMS Issues RFI on ACA’s Essential Health Benefits Framework
On Monday, the Centers for Medicare & Medicaid Services (CMS) issued a request for information (RFI) for CMS' comprehensive review of the Essential Health Benefits (EHB) framework and the requirement under the Patient Protection and Affordable Care Act (Affordable Care Act) that the scope of EHB be equal to the scope of benefits provided under a typical employer plan. CMS seeks comment on current interpretations of EHB, State approaches to selecting and updating EHB-benchmark plans, and methodologies used to determine the scope of benefits included as EHB, as well as how these approaches relate to access and market stability under the Affordable Care Act. CMS also seeks comment on variation across States in the scope of benefits included as EHB, cost pressures affecting EHB, processes for updating State EHB-benchmark plans, limitations in available data used to evaluate EHB, and potential impacts of possible future policy changes. The information gathered will inform CMS' evaluation of whether revisions or additions to the current EHB regulations through future notice and comment rulemaking may be appropriate. Comments must be received by July 15. Read the RFI here.
NIH Launches New Office to Advance Human-Based Research and Reduce Animal Use
On Monday, the National Institutes of Health announced the creation of the Office of Research Innovation, Validation, and Application to advance human-based research and reduce the use of animals in federally funded research. Housed in the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) in the NIH Office of the Director (OD), ORIVA will take a two-pronged approach. One division will support innovations in the research community by developing new funding opportunities, research infrastructure, and training resources. The other will coordinate a multi-agency effort to facilitate the evaluation and acceptance of new research methods. Read the press release here.
|